Your browser doesn't support javascript.
loading
VISTA: A promising target for overcoming immune evasion in gynecologic cancers.
Liu, Sicong; Ji, Feng; Ding, Yue; Ding, Bo; Feng, Songwei; Brennick, Cory; Lin, Hao; Zhang, Tianxiang; Shen, Yang.
Affiliation
  • Liu S; Department of Obstetrics and Gynecology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210003, China.
  • Ji F; Department of Clinical Science and Research, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China.
  • Ding Y; Department of Obstetrics and Gynecology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210003, China.
  • Ding B; Department of Obstetrics and Gynecology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210003, China.
  • Feng S; Department of Obstetrics and Gynecology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210003, China.
  • Brennick C; Department of Immunobiology, Yale University, New Haven, CT 06511, USA.
  • Lin H; Department of Clinical Science and Research, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China. Electronic address: haolin@seu.edu.cn.
  • Zhang T; Department of Immunobiology, Yale University, New Haven, CT 06511, USA. Electronic address: tianxiang.zhang@yale.edu.
  • Shen Y; Department of Obstetrics and Gynecology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210003, China. Electronic address: shenyang@seu.edu.cn.
Int Immunopharmacol ; 138: 112655, 2024 Sep 10.
Article in En | MEDLINE | ID: mdl-38986302
ABSTRACT
Immune checkpoint blockade (ICB) therapy has revolutionized cancer treatment but has shown limited efficacy in gynecologic cancers. VISTA (V-domain Ig suppressor of T-cell activation), a member of the B7 family, is emerging as another checkpoint that regulates the anti-tumor immune responses within the tumor microenvironment. This paper reviews the structure, expression, and mechanism of action of VISTA. Furthermore, it highlights recent advances in VISTA-blocking therapies and their potential in improving outcomes for patients with gynecologic cancers. By understanding the role of VISTA in mediating the immune evasion of gynecologic tumors, we can develop more effective combinatory treatment strategies that could overcome resistance to current ICB therapies.
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tumor Escape / Tumor Microenvironment / B7 Antigens / Immune Checkpoint Inhibitors / Genital Neoplasms, Female Limits: Animals / Female / Humans Language: En Journal: Int Immunopharmacol Year: 2024 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tumor Escape / Tumor Microenvironment / B7 Antigens / Immune Checkpoint Inhibitors / Genital Neoplasms, Female Limits: Animals / Female / Humans Language: En Journal: Int Immunopharmacol Year: 2024 Document type: Article